Leber Hereditary Optic Neuropathy
Leber Hereditary Optic Neuropathy
National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Leber Hereditary Optic Neuropathy is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
Related Disorders List
Information on the following diseases can be found in the Related Disorders section of this report:
Leber hereditary optic neuropathy (LHON) is mainly characterized by bilateral, painless subacute loss of central vision during young adult life. In most cases, symptoms begin with one eye first, followed a few weeks later by visual failure in the other eye. Extremely rarely there may be neurologic abnormalities, such as peripheral neuropathy, postural tremor, nonspecific myopathy, and movement disorders. LHON is caused by mutations in mitochondrial DNA and it is transmitted by maternal inheritance. LHON affects approximately 1:50,000 people. Many carriers never suffer significant visual loss; males are about four to five times more likely than females to be affected.
Individuals with LHON typically display symptoms in their young adult years. If vision is lost, then it usually occurs before 40 years of age.
The acute phase of LHON is characterized by a loss of central vision, including blurring and reduced perception of color. Individuals usually lose vision in one eye first and then lose vision in the other eye after two to three months. The atrophic phase is characterized by bilateral optic atrophy, resulting in lifelong blindness.
Depending on the mutation and pedigree, most female carriers do not lose vision but upt to half of males do.
LHON is caused by genetic mutations in the mitochondrial DNA (mtDNA). Some mothers with a LHON gene mutation do not show symptoms, but family history often reveals female relatives with visual loss at an early age.
Mutations in mitochondrial DNA can only be inherited maternally because ova contain mitochondria, while sperm do not. All of the offspring of a mother with an mtDNA mutation will inherit the gene. A male with a mitochondrial DNA mutation cannot transmit the mutated gene to any of his children.
The three primary mitochondrial DNA LHON-causing mutations are mt.3460G>A, mt.11778G>A, and mt.14484T>C, which account for over 90% of LHON patients. The most common LHON-causing mutation is mt.11778G>A. The greatest penetrance (chance of a carrier to lose vision) is for mt.3460G>A and the least is for mt.14484 T>C.
LHON affects both males and females and can only be inherited from a female. The birth prevalence of LHON is approximately 1 in 50,000 people.
Symptoms of the following disorders are similar to LHON. Comparisons may be useful for a differential diagnosis:
Autosomal Dominant Optic Atrophy (DOA). This is an autosomal genetic defect related to the OPA1 family of genes that has affect on mitochondrial biogenesis and function. The family pedigree is autosomal dominant. The symptoms tend to come on earlier than in LHON and to do so in a more insidious and milder way. Generally, before puberty the child develops slowly progressive loss of vision and central scotomas a mild optic atrophy that progresses until young adulthood to a moderate loss of vision and optic atrophy. This difference in tempo and symmetry as well as the different genetics allows for the distinction with LHON.
Toxic or nutritional deficiencies that produce a mitochondrial optic neuropathy. There are several problems with metabolism that can lead to mitochondrial dysfunction that produces an acquired optic neuropathy that seems very similar to these two genetic conditions (LHON, DOA).
LHON is diagnosed based on ophthalmologic findings, which include specialized visual testing. The testing involves dilated fundus examination to identify characteristic changes in the optic disc and vascular changes during the acute phase, electrophysiologic studies, and neuroimaging. Molecular genetic testing for mitochondrial genes associated with LHON can be used to confirm diagnosis. Most affected individuals know if their family members also are affected by LHON.
Clinical Testing and Work-Up
Consistent monitoring and surveillance of asymptomatic individuals with LHON-causing mutations is not necessary. However, if visual disturbance is experienced, affected individuals should immediately seek medical attention from an ophthalmologist or neuro-ophthalmologist .
Individuals should follow-up frequent to their own circumstances and availability of local healthcare.
Affected individuals should receive supportive management and treatment through the usage of visual aids, occupational rehabilitation, and local social services. Small studies have shown that therapies involving ubiquinone and idebenone may provide possible benefits during the acute phase of the disorder. Affected individuals should avoid smoking and excessive alcohol consumption, which causes stress to mitochondrial energy production.
Genetic counseling may be of assistance to patients and their families.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
For information about clinical trials conducted in Europe, contact:
Contact for additional information about Leber hereditary optic neuropathy:
Alfredo A. Sadun, MD, PhD
Flora Thornton Professor of Vision Research
Chief of Service, Neuro-Ophthalmology
Professor of Neuro-surgery
Keck-USC School of Medicine
1450 San Pablo St., Suite 5802
Los Angeles, CA 90033
Biousse V, Newman NJ. Leber Hereditary Optic Neuropathy. In: The NORD Guide to Rare Disorders. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003:653.
Sadun AA, Carelli V, Salomao SR, Berezovsky A, Quiros PA, Sadun F, DeNegri AM, Andrade R, Moraes M, Passos A, Kjaer P, Pereira J, Valentino ML, Schein S, Belfort R. Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy. Am J Ophthalmol. 2003 Aug;136(2):231-8.
Man PY, Griffiths PG, Brown DT, Howell N, Turnbull DM, Chinnery PF. The epidemiology of Leber hereditary optic neuropathy in the northeast of England. Am J Hum Genet. 2003;72:333-9.
Horvath R, Abicht A, Scoubridge EA, et al. Leber's hereditary optic neuropathy presenting as multiple sclerosis-like disease of the CNS. J Neurol. 2000;247:65-7.
Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG, DaCosta J, Harding AE. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain. 1995;118(pt 2):319-37.
Mashima Y, Hilda Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone. Lancet. 1992;340:368-9.
Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science. 1988;242:1427-30.
Yu-Wai-Man P, Chinnery PF. (Updated April 19, 2012). Leber Hereditary Optic Neuropathy. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2012. Available at http://www.genetests.org. Accessed December 18, 2012.
Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Leber Optic Atrophy. Entry No: 535000. Last Edited August 26, 2011. Available at: http://www.ncbi.nlm.nih.gov/omim/. Accessed December 18, 2012.
111 E 59th St
New York, NY 10022-1202
United Mitochondrial Disease Foundation
8085 Saltsburg Road Suite 201
Pittsburgh, PA 15239
National Association for Parents of Children with Visual Impairments (NAPVI)
P.O. Box 317
Watertown, MA 02272-0317
National Federation of the Blind
200 East Wells Street
at Jernigan Place
Baltimore, MD 21230
American Foundation for the Blind
2 Penn Plaza
New York, NY 10121
American Council of the Blind
2200 Wilson Boulevard
Arlington, VA 22201
Guiding Eyes for the Blind, Inc.
611 Granite Springs Road
Yorktown Heights, NY 10598
NIH/National Eye Institute
31 Center Dr
Bethesda, MD 20892-2510
Blind Children's Center
4120 Marathon Street
Los Angeles, CA 90029-3584
International Foundation for Optic Nerve Disease (IFOND)
PO Box 777
Cornwall, NY 12518
MD Support - The Eyes of the Macular Degeneration Community
3600 Blue Ridge Blvd
Grandview, MO 64030
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126
Gaithersburg, MD 20898-8126
14 Pembroke Street
Medford, MA 02155
National Ophthalmic Genotyping and Phenotyping (eyeGENE®)
National Eye Institute information office
31 Center Drive MSC 2510
Bethesda, MD 20892-2510
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email firstname.lastname@example.org
Last Updated: 1/15/2013
Copyright 1988, 1989, 1994, 1995, 1997, 2005, 2013 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.